Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Opiant Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Opiant Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Opiant Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Opiant Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Opiant Pharmaceuticals Inc, Medical Devices Deals, 2012 to YTD 2018 10
Opiant Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Opiant Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deal Details 13
Partnerships 13
Opiant Pharma Enters into Agreement with Biomedical Advanced Research and Development Authority 13
Opiant Pharma and Titan Pharma Enter into Agreement 14
Lightlake Therapeutics Enters into Agreement with University of Pennsylvania 15
Lightlake Therapeutics Enters Into Co-Development Agreement With National Institute On Drug Abuse 16
Lightlake Therapeutics Expands Co-Developmenet Agreement With National Institute On Drug Abuse 17
Lightlake Therapeutics To Enter Into Co-Development Agreement With King’s College London 18
Licensing Agreements 19
Consort Medical Enter into Development Agreement with Opiant Pharma 19
Opiant Pharma Enters into Licensing Agreement with Aegis Therapeutics 20
Opiant Pharma Enters into Licensing Agreement with Walter Reed Army Institute of Research and National Institute on Drug Abuse 22
Lightlake Therapeutics Enters into Licensing Agreement with Adapt Pharma Operations 23
Equity Offering 24
Opiant Pharma Raises USD13.8 Million in Public Offering of Shares 24
Opiant Pharma Raises USD12 Million in Public Offering of Shares 26
Opiant Pharma Raises USD5.3 Million in Private Placement of Shares up on Exercise of Warrants 27
Opiant Pharma Plans to Raise up to USD150 Million in Public Offering of Shares 28
Asset Transactions 29
Opiant Pharma Enters into Agreement with SWK for NARCAN Nasal Spray 29
Opiant Pharmaceuticals Inc – Key Competitors 30
Opiant Pharmaceuticals Inc – Key Employees 31
Opiant Pharmaceuticals Inc – Locations And Subsidiaries 32
Head Office 32
Other Locations & Subsidiaries 32
Recent Developments 33
Financial Announcements 33
Nov 07, 2018: Opiant Pharmaceuticals reports third quarter 2018 financial results and provides corporate update 33
Aug 09, 2018: Opiant Pharmaceuticals reports second quarter 2018 financial results and provides corporate update 35
May 08, 2018: Opiant Pharmaceuticals Announces First Quarter 2018 Financial Results 37
Mar 07, 2018: Opiant Pharmaceuticals Reports Financial Results for August 1, 2017, Through December 31, 2017, and Provides Corporate Update 38
Dec 04, 2017: Opiant Pharmaceuticals Reports Fiscal First Quarter 2018 Financial Results 39
Oct 13, 2017: Opiant Pharmaceuticals Reports Fiscal Fourth Quarter and Full Year 2017 Financial Results and Provides Corporate Update 40
Jun 15, 2017: Opiant Pharmaceuticals Reports Fiscal Third Quarter 2017 Financial Results and Provides Corporate Update 42
Mar 16, 2017: Opiant Pharmaceuticals Reports Fiscal Second Quarter 2017 Financial Results and Provides Corporate Update 44
Corporate Communications 45
Oct 29, 2018: Opiant Pharmaceuticals names Craig Collard to Board of Directors 45
Jun 12, 2018: Opiant Pharmaceuticals Names Richard Daly As Board Director 46
Sep 05, 2017: Opiant Pharmaceuticals Announces Appointment of David O’Toole as Chief Financial Officer 47
Aug 28, 2017: Opiant Pharmaceuticals Announces Listing on the Nasdaq Capital Market 48
Feb 06, 2017: Opiant Pharmaceuticals Announces the Appointment of Dr. Phil Skolnick as Chief Scientific Officer 49
Product News 50
02/28/2017: Opiant Pharmaceuticals Receives FDA Feedback Supporting Clinical Development of OPNT002 for the Treatment of Alcohol Use Disorder 50
Clinical Trials 51
Feb 12, 2018: Opiant Pharmaceuticals Announces Development of OPNT003, Intranasal Nalmefene, for Treatment of Opioid Overdose 51
Dec 18, 2017: Opiant Pharma Announces Publication of New Pre-Clinical Data Supporting Potential of OPNT005 as a Heroin Vaccine 52
Jul 19, 2017: Opiant Pharmaceuticals Announces Phase I Data for OPNT002 in Development for the Treatment of Alcohol Use Disorder 53
Mar 20, 2017: Opiant Pharmaceuticals Announces Initiation of Phase 2 Clinical Trial Evaluating OPNT001 in Bulimia Nervosa 54
Appendix 55
Methodology 55
About GlobalData 55
Contact Us 55
Disclaimer 55
Opiant Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Opiant Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Opiant Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Opiant Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Opiant Pharmaceuticals Inc, Deals By Therapy Area, 2012 to YTD 2018 9
Opiant Pharmaceuticals Inc, Medical Devices Deals, 2012 to YTD 2018 10
Opiant Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Opiant Pharma Enters into Agreement with Biomedical Advanced Research and Development Authority 13
Opiant Pharma and Titan Pharma Enter into Agreement 14
Lightlake Therapeutics Enters into Agreement with University of Pennsylvania 15
Lightlake Therapeutics Enters Into Co-Development Agreement With National Institute On Drug Abuse 16
Lightlake Therapeutics Expands Co-Developmenet Agreement With National Institute On Drug Abuse 17
Lightlake Therapeutics To Enter Into Co-Development Agreement With King’s College London 18
Consort Medical Enter into Development Agreement with Opiant Pharma 19
Opiant Pharma Enters into Licensing Agreement with Aegis Therapeutics 20
Opiant Pharma Enters into Licensing Agreement with Walter Reed Army Institute of Research and National Institute on Drug Abuse 22
Lightlake Therapeutics Enters into Licensing Agreement with Adapt Pharma Operations 23
Opiant Pharma Raises USD13.8 Million in Public Offering of Shares 24
Opiant Pharma Raises USD12 Million in Public Offering of Shares 26
Opiant Pharma Raises USD5.3 Million in Private Placement of Shares up on Exercise of Warrants 27
Opiant Pharma Plans to Raise up to USD150 Million in Public Offering of Shares 28
Opiant Pharma Enters into Agreement with SWK for NARCAN Nasal Spray 29
Opiant Pharmaceuticals Inc, Key Competitors 30
Opiant Pharmaceuticals Inc, Key Employees 31
Opiant Pharmaceuticals Inc, Subsidiaries 32
List of Figures
Opiant Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Opiant Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Opiant Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Opiant Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Opiant Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Opiant Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Opiant Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Opiant Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Opiant Pharmaceuticals Inc, Medical Devices Deals, 2012 to YTD 2018 10